CAncer TReatment INformed by the Molecular Tumor Board At Dartmouth

Launched by DARTMOUTH-HITCHCOCK MEDICAL CENTER · Jun 1, 2022

Keywords

ClinConnect Summary

The clinical trial titled "CAncer TReatment INformed by the Molecular Tumor Board At Dartmouth" is investigating how recommendations from a special group of doctors, called the Molecular Tumor Board, can influence treatment decisions for patients with cancer. In this study, patients will first undergo genetic testing to identify specific changes in their tumors. If eligible, their cases will be reviewed by the board, which will provide treatment suggestions that will be documented in their medical records.

To be eligible for this trial, participants must be at least 18 years old, have a tumor that shows certain genetic changes, and be in good enough health to participate. Patients will be asked to share their experiences about how the recommendations affected their treatment about 3 and 12 months after receiving them. The goal of this trial is to better understand how these expert recommendations can help doctors decide on the best treatment for their patients. It is important to note that this study does not include pregnant women and those whose tumors already have a specific mutation that has an FDA-approved treatment available.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Subject must provide verbal informed consent for study participation prior to MTB case evaluation.
• • Tumor genetic profiling performed as standard of care must include ≥100 genes.
• • Tumor must contain at least one of the following genetic alterations: (A) an alteration known to be potentially associated with sensitization to a clinically available treatment. (the list of genetic alterations evolves as new information emerges and new drugs are developed); (B) an alteration suspected to be germline.
• • Subject must have ECOG Performance Status of 0 to 2.
• • Subject must have measurable or evaluable disease.
• • Subjects who have previously enrolled in this study can be enrolled a second time if they undergo genetic profiling of a tumor that was biopsied/sampled AFTER progression on an intervening line of treatment started after the time of first enrollment. Re-enrollment of such subjects must be noted in REDCap to facilitate longitudinal analysis.
• • Age ≥18 years.
• Exclusion Criteria:
• • Subjects with a tumor harboring a genetic alteration for which an FDA-approved drug is indicated that the patient has not yet received (example for exclusion: a melanoma with a BRAF-V600E mutation in a subject who has not yet been treated with a BRAF inhibitor).
• • Pregnant women.